Langerhans cell histiocytosis (LCH) is a MAPK pathway-driven disease characterized by the accumulation of CD1a + langerin + cells of unknown origin. We have previously reported that the Notch signaling pathway is active in LCH lesions and that the Notch ligand Jagged2 (JAG2) induces CD1a and langerin expression in monocytes in vitro. Here we show that Notch signaling induces monocytes to acquire an LCH gene signature and that Notch inhibition suppresses the LCH phenotype.
INTRODUCTION
Langerhans cell histiocytosis (LCH) is a rare histiocytic disorder characterized by inflammatory lesions containing CD1a + CD207 + (langerin + ) cells. [1] [2] [3] [4] LCH has a wide spectrum of clinical manifestations ranging from single lesions, which often regress spontaneously, to severe, sometimes life-threatening multisystem disease, which requires intensive therapy. 1, 5 As LCH may occur in almost any organ-skin and bone being the most common organs involved-the presentation varies immensely. Skin LCH frequently presents as refractory eczematous rash, whereas bone LCH usually causes osteolytic bone lesions with associated soft-tissue masses. 5, 6 Genomic analysis has recently redefined our view of histiocytoses and LCH is now commonly defined as a clonal neoplasm driven by constitutive activation of MAPK signaling. 7, 8 In 50-60% of cases, the MAPK activation is driven by the BRAFV600E mutation. 9 Despite much progress in the last years, the origin of the CD1a + CD207 + LCH-cells is still unknown. 5, 10 Based on shared immunophenotypic characteristics, it was assumed that LCH arises from the eponymous epidermal Langerhans cell (LC). Comparative Abbreviations: DCs, dendritic cells; DLL1, Delta-like1; GSI, -secretase inhibitor; JAG, Jagged; LC, Langerhans cells; LCH, Langerhans cell histiocytosis; Tregs, regulatory T cells gene expression analysis suggested that the LCH cells might originate from bone marrow-derived hematopoietic cells, differ from LCs, and express a number of myeloid markers. 11, 12 Furthermore, in patients with LCH, the BRAFV600E mutation has not only been detected in bona fide CD1a + CD207 + LCH cells, but also in seemingly inconspicuous blood cells. In patients with high-risk disease, the BRAF mutation is found in peripheral blood cells, such as CD34 + cells, CD14 + monocytes, CD16 + nonclassical monocytes, and CD1c + dendritic cells (DCs). [13] [14] [15] In line, in biopsies of LCH lesions, the BRAFV600E mutation has been detected in langerin − CD14 + cells. 16 These findings support the concept that LCH arises from hematopoietic precursor cells.
However, it is not clear which cells are the immediate precursors of the CD1a + langerin + cells, and which signals induce a bone marrowderived cell to acquire the LCH-specific phenotype. 13 This question is intriguing, especially when considering that the BRAFV600E mutation is found not just in CD34 + cells of patients with LCH, but also in CD34 + cells of patients with Erdheim-Chester disease and hairy cell leukemia. 14, [17] [18] [19] The presence of identical mutations being present in the same cell type in clinically very distinct diseases implies that the BRAFV600E mutation alone is not instructive for a cell to develop an LCH phenotype.
We have previously shown that the Notch pathway is active in TGF-and GM-CSF induces CD1a and langerin expression in human CD14 + monocytes. 11 Recently, it was proposed that both CD1c + DCs and CD14 + monocytes might give rise to LCH as BRAFV600E is detected in both cell subsets in patients with LCH. In addition, both cell types can be induced to express CD1a and langerin upon stimulation with exogenous signals, among them Notch ligands. 14 However, two surface markers do not suffice to determine a cellular phenotype. 11, 12 We therefore set out to examine the effects of Notch signaling on monocyte and DC differentiation in more depth and investigated if langerin + cells derived from CD1c + DCs and CD14 + monocytes differ from each other. In particular, we asked whether these cell types acquire an LCH-like phenotype in vitro and which of them may represent the immediate precursor population of LCH cells.
MATERIAL AND METHODS

Patient samples
This study was conducted in accordance with the Declaration of Helsinki after approval by the local institutional review board, and after obtaining written and informed consent.
Isolation and cultivation of cells
T cells were isolated from PBMCs using CD4 + naïve T cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were isolated from PBMCs using CD14 Monocyte Isolation Kit II, CD16 Monocyte, or CD1c Isolation Kit (Miltenyi Biotec); cultured with 100 ng/ml GM-CSF and 10 ng/ml TGF-1; and where indicated with IL-4 400 U/ml (PeproTech, Rocky Hill, NJ, USA) in CellGro (CellGenix, Freiburg im Breisgau, Germany). Cell isolation purity was assessed by flow cytometry and purities of above 95% were achieved. Notch inhibitor (RO-4929097, Santa Cruz Biotechnology, Dallas, TX, USA) was used at 1 M.
Plating of cells on ligands
Cell culture dishes were coated with anti-IgG (Biomedica, Vienna, Austria, goat anti-human IgG) 10 g/ml for 30 min at 37 • C diluted in PBS.
After washing with PBS, blocking with complete growth media for 30 min at 37 • C, and a second washing, plates were coated with Jagged (JAG)2/Fc, JAG1/Fc, Delta-like1 (DLL1)/Fc (R&D Systems Inc., Minneapolis, MN, USA), or human IgG (Privigen, CSL Behring, King of Prussia, PA, USA) in RPMI without serum. 20 Gene reporter assays were performed using an Recombining binding protein suppressor of hairless (RBPJ) luciferase construct (Qiagen, Hilden, Germany). A total of 200,000 monocytes were platted in 24 wells coated either with JAG1, JAG2, DLL1, or human IgG and transfected with 300 ng/well luciferase gene reporter construct (CCS-014L) using Viromer RED (Lipocalyx, Halle, Germany) according to manufacturer's instructions. A negative control plasmid without RBPJ binding elements was used as control. 
FACS staining
BRAFV600E analysis
DNA was either isolated from whole blood or from FACS sorted cell subsets using the QIAamp DNA blood mini kit (Quiagen, Germany).
Allele-specific qPCR was performed as described previously. 15 Viability assay was performed using CellTiter-Glo Luminescent Cell Viability Assay (Promega, Fitchburg, WI, USA) according to manufacturer's instructions.
Gene expression analysis
Normalization of CEL files and all further analyses were performed in R statistical environment using Bioconductor packages. 21 Affymetrix CEL files were normalized using frma 22 using the "summarize = robust_weighted_average" setting. To account for batch effects in the different dataset, "ComBat" 23 function from the "sva" package was used. ComBat normalized data were further filtered by the z-score calculated with the "barcode" function of the frma package. Genes with z-scores <2 in all samples were excluded and finally the probeset with the highest variance across samples per gene was chosen for further analysis. Data was submitted to Gene Expression Omnibus (GSE114181).
T cell proliferation assay and cytokine measurement
CD14 + monocytes and CD1c + DCs were seeded on JAG2-coated cell culture dishes and sorted for CD1a − CD207 − , CD1a + CD207 − , and 
RESULTS
We first intended to define which cells can give rise to LCH-like cells in vitro. Langerin + cells can be generated in vitro from human CD14 + monocytes and CD1c + DCs using different protocols. 11, [24] [25] [26] [27] Based on the high expression of JAG1 and JAG2 in LCH lesions 11, 28 and as we have previously shown that JAG2 induces CD1a and langerin expression in CD14 + monocytes, 11 we first focused our analysis on JAG1 and JAG2. In addition, we studied DLL1, which was reported to induce CD1a and langerin in CD14 + monocytes and CD1c + DCs. 14, 29 CD1c + DCs and CD14 + monocytes were isolated from healthy donors, plated on Notch ligand-coated surfaces and subsequently ana- Fig. 1A and B lower panel). Based on our previous results demonstrating the importance of JAG2 for an LCH phenotype development, we focused on JAG2 in our subsequent experiments. As the BRAFV600E mutation was also detected in CD14 − CD11c + cells, which include CD16 + nonclassical monocytes, we also analyzed CD16 + cells in this set of experiments. 13 In contrast to classical CD14 + monocytes, CD16 + nonclassical monocytes failed consistently to acquire CD1a −
and langerin − for all tested donors and were therefore not included in further studies (Supplementary Fig. S1A and B).
Next, we wanted to determine whether and which of the This analysis showed that JAG2-stimulated CD14 + monocytes were more similar to primary LCH cells (Fig. 1C) , whereas IL-4 or JAG2 stimulation of CD14 + monocytes resulted in distinct transcriptional profiles (482 significantly differentially expressed genes; |logFC| > 1.5, P < 0.05; Supplementary File 1/Sheet 5).
Next, we asked which pathways contribute to the generation of the LCH-specific gene signature in JAG2-differentiated monocytes in comparison to IL-4-treated monocytes. To this end, we performed KEGG pathway analysis, which identified 21 significantly enriched pathways.
Most of them were associated with inflammation, bone resorption, and granuloma formation, all key characteristics of LCH lesions that frequently include osteolysis and granuloma formation. 30 In line with the inflammatory response, the TNF signaling pathway was significantly up-regulated in JAG2-stimulated langerin + CD14 monocytes ( Supplementary Fig. S1C ).
Langerin + cells derived from CD1c + DC and IL-4-treated CD14 + monocytes showed overlapping characteristics and clustered next to each other. As expected, freshly isolated CD14 + monocytes and CD1c + DCs were most distant in their transcriptional profile to primary LCH samples (Fig. 1C) .
Principle component analysis confirmed the high similarity of primary LCH cells and JAG2-stimulated CD14 + monocytes, confirming the proximity of these two cell types at transcriptional level (Fig. 1D) . In the same analysis, langerin + cells derived from CD1c + DC and IL-4-treated CD14 + monocytes clustered close to each other.
We next searched for genes that were highly expressed in LCH and specifically up-regulated in JAG2-stimulated CD14 + monocytes in comparison to langerin + cells derived from CD1c + DC. This analysis uncovered a number of potential relevant candidate genes for LCH pathogenesis including DKK2. DKK2 has been described to trigger osteolysis, a key feature of bone LCH, 31, 32 and to induce inflammation-associated markers, such as S100A8, S100A9, 33 Fig. S1D ).
In the next step, we selected genes that were differentially regulated when comparing langerin + cells derived from JAG2-stimulated CD1c + cells and primary LCH cells (P < 0.01), and at the same time similar when comparing langerin + cells derived from JAG2-differentiated CD14 + monocytes and primary LCH cells (P > 0.5). KEGG pathway analyses of these genes were in line with the previous analysis (Supplementary Fig. S1D ). In addition to the Notch pathway, the Rap1 signaling Unsupervised hierarchical clustering shows that the JAG2 stimulated monocytes cluster next to the LCH cells: heatmap (constructed using the R function "pheatmap" with default settings) of a correlation matrix samples using the 12,751 most variable genes in the dataset. The color bar indicates the correlation coefficient (R). CD1a + langerin + sorted populations derived from CD14 + monocytes on JAG2 (CD14JAG2), CD14 + monocytes with the addition of IL-4 (CD14IL4), CD1c + on JAG2 (CD1cJAG2), and CD1c + on IgG (CD1cIgG) control all in the presence of TGF-1 and GM-CSF and gene expression profiling was performed using Affymetrix arrays. The data were analyzed together with RNA from the corresponding freshly isolated monocytes and CD1c + cells, and our previous dataset harboring in addition LCH cells from biopsies of 8 different patients with LCH, LC isolated from skin. 11 Capital letters indicate different healthy donors. (D) Principal component analysis was performed using the R function "princomp" with default settings and TNF signaling pathways were among the top enriched pathways (Supplementary Fig. S1E ).
To test whether the similarity can be confirmed with respect to LCH signature genes, the analysis was rerun with a manually curated limited LCH specific signature consisting of 13 genes ( Supplementary Fig. S2A and B). 5, 11, 12, 35, 36 Again, CD14 + monocytes stimulated with NOTCH ligand JAG2 clustered closest to primary LCH cells (Supplementary Fig.   S2A ). Analyzing the expression level of those LCH signature genes in the different langerin + subsets in more detail, ITGAM (CD11b), ITGAX (CD11c), and CD14 were found to be significantly higher expressed in LCH and CD14 + monocytes on JAG2, compared to CD1c + cells on JAG2 or IgG. In contrast, CDH1 (E-Cadherin, CD324) and CCR7, which were both expressed at low levels in LCH and CD14 + monocytes on JAG2, were high in CD1c + -derived langerin + cells (Supplementary Fig. S2A and B) . In addition, the total number of differentially regulated genes (|logFC| > 1.5, P < 0.05) was lowest between monocytes differentiated on JAG2 and LCH cells ( Supplementary Fig. S2C and D). Together, these data corroborate the close relationship between primary LCH cells and CD1a + CD207 + positive cells generated from JAG2-stimulated monocytes.
To characterize langerin + cells derived from CD1c + and CD14 + cells also in respect to cell surface markers, we performed flow cytometric profiling. CD1a + CD207 + positive cells isolated from an LCH biopsy were used as control ( Fig. 2A) . 5, 11, 12, [35] [36] [37] The flow cytometric analyses showed that langerin + cells derived from CD14 + monocytes expressed higher levels of CD14, CD163, CD1c, CD11b (ITGAM), and CD196 (CCR6) than langerin + cells derived from CD1c + DCs. CD11c (ITGAX), CD33, CD1d, and CD304 (NRP1) surface expression were similar on both cell subtypes (Fig. 2B ). E-Cadherin (CD324) and CD197 (CCR7), which are expressed at low levels in LCH, 35, 36 were lower on langerin + cells derived from CD14 + monocytes than on cells derived from CD1c + DCs (Fig. 2C ). In accordance with the reported low levels of CD86 and CD83 on LCH cells, 38 cell surface staining for these markers was low in both langerin + subsets (Fig. 2D) . Taken together, the surface phenotype of the JAG2-stimulated CD14 + monocytes substantiates our finding at the gene expression level.
Once we had established that JAG2 specifically induced an LCH signature in CD14 + monocytes, we asked whether JAG2 directly activates the Notch pathway via RBPJ, the major transcriptional effector of Notch signaling. 39 CD14 + monocytes were seeded on either IgG control or Notch ligand-coated dishes, transfected with an RBPJ luciferase gene reporter construct, and luciferase activity was analyzed 48h thereafter. The Notch ligands DLL1 and JAG1, which are both expressed in LCH but at lower levels than JAG2, 11, 28 caused no or only slight induction of luciferase activity compared to IgG control conditions. In contrast, JAG2 induced on average a 3-fold promoter activation (Fig. 3A) , suggesting that JAG2 directly activates the classical Notch pathway in CD14 + monocytes.
Notch inhibitors are currently evaluated in clinical trials for a broad range of cancers and would also be available for the treatment of LCH. 40 To test whether Notch inhibition has an effect on langerin + cells derived either from CD1c + or CD14 + cells, we treated these cells with the small molecule -secretase inhibitor (GSI) RO-4929097.
RO4929097 is a potent and selective inhibitor of -secretase that leads to a blockade of Notch signaling. 41 In line with our previous results, Notch pathway activation was crucial for the differentiation of CD14 + monocytes into langerin + cells (Fig. 3B/C ) and was efficiently blocked by GSI treatment, whereas CD1c + DCs were not affected. This led us to conclude that the Notch pathway is not required for CD1a and langerin induction in CD1c + DCs. This is in line with the observation that CD1c + DCs already differentiate toward CD1a + CD207 + cells in the presence of TGF-and GM-CSF in the absence of Notch pathway stimulation ( Fig. 1A and B) .
To assess the viability of CD14 + monocytes seeded either on IgG control or JAG2-coated plates, we used the CellTiter-Glo R Luminescent Cell Viability Assay 96h after seeding the cells. In comparison to control conditions, JAG2 stimulation of CD14 + monocytes increased cell viability about 1.5-fold (Fig. 4A) . This is reflected in the functional annotation analysis 42 of genes differentially regulated between CD14 + and JAG2-stimulated CD14 + monocytes, demonstrating a significant enrichment of cell cycle-associated pathways ( Supplementary Fig. S3E ).
Skin and bone are the most frequently affected tissues in patients with LCH, with an involvement of bone in 75-80% of cases. 43 A key feature of bone LCH is osteolysis. 6 We therefore analyzed the capability of JAG2-stimulated CD14 + monocytes to induce collagen release as a marker of bone degradation. We seeded CD14 + monocytes on of the total available collagen, with no significant difference between CD207 − and CD207 + cells (Fig. 4B ). This indicates that CD1a + cells derived from CD14 + monocytes are able to induce collagen release from human bone matrix, a prerequisite of bone degradation, which is one of the main features of bone LCH. 44 To further functionally characterize langerin + cells derived from CD14 + monocytes, we investigated their ability to induce T cell proliferation and analyzed these T cells for their surface marker profile.
We stimulated CD14 + (Fig. 5A and B In subsequent experiments, we expanded our analysis of CD25 + CD127 − CD39 + cells derived from CD4 + T cells cultivated with CD1a + CD207 + and performed a FoxP3 staining, demonstrating that these supposedly Tregs express the bona fide Treg marker FoxP3 in a high proportion of cells (Fig. 5C) . 48 In addition, we measured cytokine levels in the supernatant of CD1a + CD207 + cells cocultured with CD4 + T cells. IL-10 and TGF-1, which are both key immune-suppressive cytokines produced by Tregs, were detected in the supernatant (Fig. 5 D,E) . 49, 50 Furthermore, we measured cytokine levels of IL-1a, IL-7, IL-17, TNF-, and IFN-, which have previously been shown to be up-regulated in LCH lesions. 51, 52 The most abundant cytokine was IFN-, followed by TNF-. Only very low levels of IL-17A were detected, and IL-1A and IL-7 were hardly detected or not at all. The finding that CD1a + CD207 + cells are able to induce Tregs is in agreement with a previous study reporting the presence of Tregs and IL-10 in LCH lesions and higher levels of Tregs in the blood of patients with LCH compared to healthy children. 53 In line, when we analyzed T cells isolated from an LCH biopsy, we found CD25 + CD127 − CD39 + cells (Supplementary Fig. S1B ). Together, these data show that CD1a + langerin + derived from CD14 + monocytes are functionally active and can induce the proliferation of supposedly Tregs.
DISCUSSION
Defining the cell of origin of LCH is necessary to better understand the pathogenesis of this disease. Historically, it was assumed that LCH arises from LC due to the presence of Birbeck granules, which are a hallmark feature of these cells. However, recent findings challenge this When we analyzed peripheral blood from a patient with multisystem LCH, we found the BRAFV600E mutation in both CD1c + DCs and CD14 + monocytes ( Supplementary Fig. S3B and C), which is in line with previous reports that observed BRAFV600E positive cells in different hematopoietic lineages, such as monocytes, lymphocytes, and DCs. 13 However, when we calculated the absolute numbers of BRAFV600E + cell, we found that CD1c + cells were extremely rare ( Supplementary   Fig. S3C ). CD14 + cells might therefore be more likely to contribute to disease burden in this patient.
We then tested the effect of the Notch inhibitor GSI RO-4929097 on CD14 + and CD1c + cells and found that Notch inhibition had no effect on CD1c + DCs, whereas CD14 + monocytes on JAG2 did 
